JB Ashtin celebrates 25 years of supporting medical miracles

August 09, 2024 12:00 AM AEST | By EIN Presswire
 JB Ashtin celebrates 25 years of supporting medical miracles
Image source: EIN Presswire

PLYMOUTH, MI, UNITED STATES, August 8, 2024 /EINPresswire.com/ -- JB Ashtin, a woman-owned business enterprise founded and headquartered in Michigan, is celebrating 25 years of supporting new pharmaceutical treatments that have helped improve the health and wellbeing of people across the United States and around the world.

Founded in 1999 by CEO Joni Bradley, PharmD, JB Ashtin is a medical communications agency dedicated to creating and bringing groundbreaking scientific narratives to life. The agency’s partnership with pharmaceutical, biotechnology, consumer health, and medical device companies has positioned JB Ashtin at the forefront of transforming complex data into compelling stories that resonate with healthcare experts, practitioners, and patients alike.

The many medical miracles JB Ashtin has helped introduce to patients include:

2001: Adderall XR® for the treatment of adults with ADHD, which Bradley says “can be life-changing in terms of academic, life, and work success. This medication saves jobs, marriages, and in some cases lowers the risk for suicide.”

2003-2007: Soliris® (eculizumab) for PNH (paroxysmal nocturnal hemoglobinuria) — the very first treatment for this rare disease that can attack red blood cells, induce fatigue, and lead to death

2013-2020: Humira® (adalimumab), an immunosuppressive that can treat arthritis, plaque psoriasis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.

2024: Nomlabofusp for Freidrich's ataxia, a rare, inherited, and progressive, neurodegenerative movement disorder that reduces patients’ quality of life and life expectancy.

“We know that every treatment we build awareness for helps someone who needs it,” Bradley said. “Each one represents a life-changing impact, whether it’s helping someone battle Crohn’s disease, or a person traumatized by Parkinson’s or in the case of Rethymic®, provide hope for those with congenital athymia, which is otherwise fatal in childhood. It’s an honor to do this work.”

“The one thing clients tell us repeatedly is that they trust us,” Bradley said. “They trust our expertise, experience, and leadership. They’re confident our scientific storytellers will deliver compelling narratives and that we’ll manage the process well, so they can focus their energy where it will have the greatest impact – on bringing new treatments to people who need them.”

“There is the top of the pyramid of people who you like working with, who do good work, and you completely and totally trust,” said Marianne Andreach, former SVP Product Planning, Esperion. “That’s JB Ashtin.”

Over the course of its 25 years, JB Ashtin has grown from $150,000 to more than $5,000,000 in revenue to match the demand for its work by a growing number of innovative healthcare clients.

In recognition of its 25th anniversary, JB Ashtin has compiled a list of 25 medical miracles — true advancements in the treatment of illness, several of which the agency has supported — that it will be spotlighting on social media and its own website through the rest of 2024.

“In some ways, the news every day seems so dire. But when it comes to medical science, things are getting better and better,” Bradley said. “We think people are ready to hear some good news.”

--30--

Lee Wochner
Counterintuity
+1 818-616-8345
email us here
Visit us on social media:
LinkedIn
Instagram


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.